The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC).
Denise Aysel Yardley
Consultant or Advisory Role - Genentech/Roche (U)
Debu Tripathy
No relevant relationships to disclose
Adam M. Brufsky
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Research Funding - Genentech/Roche
Hope S. Rugo
Research Funding - Genentech/Roche
Peter Andrew Kaufman
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Research Funding - Genentech/Roche
Musa Mayer
No relevant relationships to disclose
Shibao Feng
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Genentech/Roche
Oyewale O. Abidoye
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Genentech/Roche
Marianne Ulcickas Yood
Research Funding - Genentech/Roche